Shanghai Fosun Pharmaceutical Group Co Stock

Shanghai Fosun Pharmaceutical Group Co P/S 2024

Shanghai Fosun Pharmaceutical Group Co P/S

1.39

Ticker

600196.SS

ISIN

CNE000000X38

As of Sep 6, 2024, Shanghai Fosun Pharmaceutical Group Co's P/S ratio stood at 1.39, a -29.44% change from the 1.97 P/S ratio recorded in the previous year.

The Shanghai Fosun Pharmaceutical Group Co P/S history

Shanghai Fosun Pharmaceutical Group Co Aktienanalyse

What does Shanghai Fosun Pharmaceutical Group Co do?

Shanghai Fosun Pharmaceutical Group Co Ltd is a Chinese company specializing in the healthcare industry. It was founded in 1994 and is headquartered in Shanghai. The company has grown to become one of the largest pharmaceutical conglomerates in China and operates internationally. The company's history began in the 1990s with the establishment of Shanghai Fosun High-Tech (Group) Co. Ltd. Through the acquisition of local pharmaceutical companies, Fosun quickly secured a place among the major players in the Chinese pharmaceutical market. From the beginning, the development, production, and marketing of pharmaceutical products and medical devices were the main focus. Today, Shanghai Fosun Pharmaceutical is a holding company with various subsidiaries operating in different areas of medicine. These include the development of innovative drugs, the production of generic drugs, and the business-to-consumer sector. The company generates an annual revenue of over six billion US dollars. One of Shanghai Fosun Pharmaceutical's most well-known products is the drug Alunbrig for the treatment of lung cancer. It is a tyrosine kinase inhibitor that inhibits the growth of cancer cells. Alunbrig has shown good results in clinical studies and is now approved for the treatment of lung cancer in many countries. Another important business area for Shanghai Fosun Pharmaceutical is the production of generic drugs. These are imitations of already approved, often expensive, original drugs. Fosun manufactures such medications at a significantly lower cost than the original manufacturer, making them more accessible to a broader population. In addition to drug development and generic production, Shanghai Fosun Pharmaceutical is also active in other areas of the healthcare industry. In recent years, the company has acquired several private hospitals in China and operates them under the name Fosun International Hospitals. Special emphasis is placed on state-of-the-art medical technology and patient-oriented care. Another important area is the manufacturing of medical devices. Shanghai Fosun Pharmaceutical works closely with partners from both domestic and foreign markets to develop innovative products. An example is the artificial hip joint, which was developed in collaboration with an American partner company. Fosun produces and distributes over 70 different types of medical devices. In summary, Shanghai Fosun Pharmaceutical Group is an innovative company specializing in various areas of the healthcare industry. Through its consistent focus on growth and innovation, Fosun has steadily expanded in recent years and has become one of the key players in the Chinese pharmaceutical market. However, the global expansion and ambitious goals also leave room for risks and mistakes. Shanghai Fosun Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Shanghai Fosun Pharmaceutical Group Co's P/S Ratio

Shanghai Fosun Pharmaceutical Group Co's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Shanghai Fosun Pharmaceutical Group Co's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Shanghai Fosun Pharmaceutical Group Co's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Shanghai Fosun Pharmaceutical Group Co’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Shanghai Fosun Pharmaceutical Group Co stock

What is the price-to-earnings ratio of Shanghai Fosun Pharmaceutical Group Co?

The price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co is currently 1.39.

How has the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co changed compared to last year?

The price-to-earnings ratio of Shanghai Fosun Pharmaceutical Group Co has increased by -29.44% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co high compared to other companies?

Yes, the price-to-earnings ratio of Shanghai Fosun Pharmaceutical Group Co is high compared to other companies.

How does an increase in the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co affect the company?

An increase in the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Shanghai Fosun Pharmaceutical Group Co affect the company?

A decrease in the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co?

Some factors that influence the price-earnings ratio of Shanghai Fosun Pharmaceutical Group Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Shanghai Fosun Pharmaceutical Group Co pay?

Over the past 12 months, Shanghai Fosun Pharmaceutical Group Co paid a dividend of 0.42 CNY . This corresponds to a dividend yield of about 1.86 %. For the coming 12 months, Shanghai Fosun Pharmaceutical Group Co is expected to pay a dividend of 0.44 CNY.

What is the dividend yield of Shanghai Fosun Pharmaceutical Group Co?

The current dividend yield of Shanghai Fosun Pharmaceutical Group Co is 1.86 %.

When does Shanghai Fosun Pharmaceutical Group Co pay dividends?

Shanghai Fosun Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of August, July, September, September.

How secure is the dividend of Shanghai Fosun Pharmaceutical Group Co?

Shanghai Fosun Pharmaceutical Group Co paid dividends every year for the past 23 years.

What is the dividend of Shanghai Fosun Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.44 CNY are expected. This corresponds to a dividend yield of 1.97 %.

In which sector is Shanghai Fosun Pharmaceutical Group Co located?

Shanghai Fosun Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Fosun Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Fosun Pharmaceutical Group Co from 8/6/2024 amounting to 0.27 CNY, you needed to have the stock in your portfolio before the ex-date on 8/6/2024.

When did Shanghai Fosun Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 8/6/2024.

What was the dividend of Shanghai Fosun Pharmaceutical Group Co in the year 2023?

In the year 2023, Shanghai Fosun Pharmaceutical Group Co distributed 0.56 CNY as dividends.

In which currency does Shanghai Fosun Pharmaceutical Group Co pay out the dividend?

The dividends of Shanghai Fosun Pharmaceutical Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Fosun Pharmaceutical Group Co

Our stock analysis for Shanghai Fosun Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Fosun Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.